Cell salvage processing of residual cardiopulmonary bypass volume in minimally invasive cardiac surgery
- 41 Downloads
Several reports demonstrated positive effects of processing residual cardiopulmonary bypass volume using a cell salvage device in conventional open heart surgery via sternotomy on hemostasis. The present study aimed to investigate whether cell salvage processing has the same effects on postoperative blood loss and transfusion in minimally invasive cardiac surgery. Between July 2015 and April 2018, 80 consecutive patients undergoing minimally invasive aortic valve replacement via right anterolateral minithoracotomy were enrolled in the present study. Perioperative outcomes and coagulation data of 40 patients who were retransfused with processed cardiopulmonary bypass volumes were compared with those of 40 patients receiving unprocessed residual blood (control group). Postoperative blood loss in patients receiving processed residual blood was significantly less than that in the control group at 6 h (115 ± 50 vs. 73 ± 33 ml, p < 0.001) and 12 h (167 ± 70 vs. 125 ± 67 ml, p = 0.009) after surgery, and the rate of fresh frozen plasma use after surgery was significantly reduced in patients receiving processed residual blood (18 vs. 0%, p = 0.012). In conclusion, processing of residual cardiopulmonary bypass volume reduced postoperative blood loss and postoperative use of fresh frozen plasma and could be useful for hemostasis in minimally invasive cardiac surgery.
KeywordsCell salvage device Minimally invasive cardiac surgery Residual cardiopulmonary bypass volume Postoperative blood loss
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 2.Society of Thoracic Surgeons Blood Conservation Guideline Task Force, Ferraris VA, Brown JR, Despotis GJ, Hammon JW, Reece TB, Saha SP, Song HK, Clough ER, Society of Cardiovascular Anesthesiologists Special Task Force on Blood Transfusion, Shore-Lesserson LJ, Goodnough LT, Mazer CD, Shander A, Stafford-Smith M, Waters J, International Consortium for Evidence Based Perfusion, Baker RA, Dickinson TA, FitzGerald DJ, Likosky DS, Shann KG (2011) 2011 update to the Society of Thoracic Surgeons and the Society of cardiovascular anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg 91:944–982CrossRefGoogle Scholar
- 10.de Haan J, Schönberger J, Haan J, van Oeveren W, Eijgelaar A (1993) Tissue-type plasminogen activator and fibrin monomers synergistically cause platelet dysfunction during retransfusion of shed blood after cardiopulmonary bypass. J Thorac Cardiovasc Surg 106:1017–1023Google Scholar
- 13.Kato GJ, McGowan V, Machado RF, Little JA, Taylor J VI, Morris CR, Nichols JS, Wang X, Poljakovic M, Morris SM Jr, Gladwin MT (2006) Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood 107:2279–2285CrossRefGoogle Scholar
- 14.Rubens FD, Boodhwani M, Mesana T, Wozny D, Wells G, Nathan HJ (2007) Cardiotomy Investigators. The cardiotomy trial: a randomized, double-blind study to assess the effect of processing of shed blood during cardiopulmonary bypass on transfusion and neurocognitive function. Circulation 116:I89–I97CrossRefGoogle Scholar
- 15.Scrascia G, Rotunno C, Nanna D, Rociola R, Guida P, Rubino G, Schinosa L, Paparella D (2012) Pump blood processing, salvage and re-transfusion improves hemoglobin levels after coronary artery bypass grafting, but affects coagulative and fibrinolytic systems. Perfusion 27:270–277CrossRefGoogle Scholar